SEC Form 4 · accession 0001209191-19-012695
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Carey
Officer — EVP, Chief Business Officer
Period of report
Feb 20, 2019
Accepted (ET)
Feb 22, 2019 · 5:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Feb 20, 2019 | A | 72,375 | $0.00 | A | 72,375 | D | |
| Ordinary Shares | Feb 20, 2019 | F | 32,064 | $21.54 | D | 40,311 | D | |
| Ordinary SharesF2 | holding | — | — | — | 208,780 | I | By Robert F. Carey III Trust dated 4.24.01 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met.
- F2Includes 36,276 shares previously reported as directly held by the Reporting Person.